High-risk medulloblastoma

a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031).

Nancy J. Tarbell, Henry Friedman, William R. Polkinghorn, Torunn Yock, Tianni Zhou, Zhengjia Chen, Peter Burger, Patrick Barnes, Larry Kun

Research output: Contribution to journalArticle

Abstract

To compare event-free survival (EFS) in children with high-risk medulloblastoma randomly assigned to receive either chemotherapy before radiation or chemotherapy after radiation. One hundred twelve patients were randomly assigned to each arm. Criteria used to categorize patients as high risk included M1-4 disease by modified Chang staging classification, T3b/T4 disease, or greater than 1.5 cm3 of residual tumor after surgery. Postoperatively, children with high-risk medulloblastoma were randomly assigned to two arms, either chemotherapy entailing three cycles of cisplatin and etoposide before radiation (chemotherapy first [CT1]) or the same chemotherapy regimen after radiation (radiation therapy first [RT1]). Both groups received consolidation chemotherapy consisting of vincristine and cyclophosphamide. The median follow-up time was 6.4 years. Five-year EFS was 66.0% in the CT1 arm and 70.0% in the RT1 arm (P = .54), and 5-year overall survival in the two groups was 73.1% and 76.1%, respectively (P = .47). In the CT1 arm, 40 of the 62 patients with residual disease achieved either complete or partial remission. Five-year EFS did not differ significantly whether, after surgery, patients received chemotherapy before or after radiotherapy.

Original languageEnglish (US)
Pages (from-to)2936-2941
Number of pages6
JournalJournal of Clinical Oncology
Volume31
Issue number23
StatePublished - Aug 10 2013

Fingerprint

Medulloblastoma
Radiotherapy
Pediatrics
Drug Therapy
Radiation
Disease-Free Survival
Consolidation Chemotherapy
Residual Neoplasm
Vincristine
Etoposide
Cyclophosphamide
Cisplatin
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Tarbell, N. J., Friedman, H., Polkinghorn, W. R., Yock, T., Zhou, T., Chen, Z., ... Kun, L. (2013). High-risk medulloblastoma: a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031). Journal of Clinical Oncology, 31(23), 2936-2941.

High-risk medulloblastoma : a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031). / Tarbell, Nancy J.; Friedman, Henry; Polkinghorn, William R.; Yock, Torunn; Zhou, Tianni; Chen, Zhengjia; Burger, Peter; Barnes, Patrick; Kun, Larry.

In: Journal of Clinical Oncology, Vol. 31, No. 23, 10.08.2013, p. 2936-2941.

Research output: Contribution to journalArticle

Tarbell, NJ, Friedman, H, Polkinghorn, WR, Yock, T, Zhou, T, Chen, Z, Burger, P, Barnes, P & Kun, L 2013, 'High-risk medulloblastoma: a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031).', Journal of Clinical Oncology, vol. 31, no. 23, pp. 2936-2941.
Tarbell, Nancy J. ; Friedman, Henry ; Polkinghorn, William R. ; Yock, Torunn ; Zhou, Tianni ; Chen, Zhengjia ; Burger, Peter ; Barnes, Patrick ; Kun, Larry. / High-risk medulloblastoma : a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031). In: Journal of Clinical Oncology. 2013 ; Vol. 31, No. 23. pp. 2936-2941.
@article{28210ced05254bcab8da701649d3fb00,
title = "High-risk medulloblastoma: a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031).",
abstract = "To compare event-free survival (EFS) in children with high-risk medulloblastoma randomly assigned to receive either chemotherapy before radiation or chemotherapy after radiation. One hundred twelve patients were randomly assigned to each arm. Criteria used to categorize patients as high risk included M1-4 disease by modified Chang staging classification, T3b/T4 disease, or greater than 1.5 cm3 of residual tumor after surgery. Postoperatively, children with high-risk medulloblastoma were randomly assigned to two arms, either chemotherapy entailing three cycles of cisplatin and etoposide before radiation (chemotherapy first [CT1]) or the same chemotherapy regimen after radiation (radiation therapy first [RT1]). Both groups received consolidation chemotherapy consisting of vincristine and cyclophosphamide. The median follow-up time was 6.4 years. Five-year EFS was 66.0{\%} in the CT1 arm and 70.0{\%} in the RT1 arm (P = .54), and 5-year overall survival in the two groups was 73.1{\%} and 76.1{\%}, respectively (P = .47). In the CT1 arm, 40 of the 62 patients with residual disease achieved either complete or partial remission. Five-year EFS did not differ significantly whether, after surgery, patients received chemotherapy before or after radiotherapy.",
author = "Tarbell, {Nancy J.} and Henry Friedman and Polkinghorn, {William R.} and Torunn Yock and Tianni Zhou and Zhengjia Chen and Peter Burger and Patrick Barnes and Larry Kun",
year = "2013",
month = "8",
day = "10",
language = "English (US)",
volume = "31",
pages = "2936--2941",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "23",

}

TY - JOUR

T1 - High-risk medulloblastoma

T2 - a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031).

AU - Tarbell, Nancy J.

AU - Friedman, Henry

AU - Polkinghorn, William R.

AU - Yock, Torunn

AU - Zhou, Tianni

AU - Chen, Zhengjia

AU - Burger, Peter

AU - Barnes, Patrick

AU - Kun, Larry

PY - 2013/8/10

Y1 - 2013/8/10

N2 - To compare event-free survival (EFS) in children with high-risk medulloblastoma randomly assigned to receive either chemotherapy before radiation or chemotherapy after radiation. One hundred twelve patients were randomly assigned to each arm. Criteria used to categorize patients as high risk included M1-4 disease by modified Chang staging classification, T3b/T4 disease, or greater than 1.5 cm3 of residual tumor after surgery. Postoperatively, children with high-risk medulloblastoma were randomly assigned to two arms, either chemotherapy entailing three cycles of cisplatin and etoposide before radiation (chemotherapy first [CT1]) or the same chemotherapy regimen after radiation (radiation therapy first [RT1]). Both groups received consolidation chemotherapy consisting of vincristine and cyclophosphamide. The median follow-up time was 6.4 years. Five-year EFS was 66.0% in the CT1 arm and 70.0% in the RT1 arm (P = .54), and 5-year overall survival in the two groups was 73.1% and 76.1%, respectively (P = .47). In the CT1 arm, 40 of the 62 patients with residual disease achieved either complete or partial remission. Five-year EFS did not differ significantly whether, after surgery, patients received chemotherapy before or after radiotherapy.

AB - To compare event-free survival (EFS) in children with high-risk medulloblastoma randomly assigned to receive either chemotherapy before radiation or chemotherapy after radiation. One hundred twelve patients were randomly assigned to each arm. Criteria used to categorize patients as high risk included M1-4 disease by modified Chang staging classification, T3b/T4 disease, or greater than 1.5 cm3 of residual tumor after surgery. Postoperatively, children with high-risk medulloblastoma were randomly assigned to two arms, either chemotherapy entailing three cycles of cisplatin and etoposide before radiation (chemotherapy first [CT1]) or the same chemotherapy regimen after radiation (radiation therapy first [RT1]). Both groups received consolidation chemotherapy consisting of vincristine and cyclophosphamide. The median follow-up time was 6.4 years. Five-year EFS was 66.0% in the CT1 arm and 70.0% in the RT1 arm (P = .54), and 5-year overall survival in the two groups was 73.1% and 76.1%, respectively (P = .47). In the CT1 arm, 40 of the 62 patients with residual disease achieved either complete or partial remission. Five-year EFS did not differ significantly whether, after surgery, patients received chemotherapy before or after radiotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84886726351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886726351&partnerID=8YFLogxK

M3 - Article

VL - 31

SP - 2936

EP - 2941

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 23

ER -